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Tissue particle retentionWe investigated gene expression, protein synthesis, and particle retention in mouse lungs following intratracheal
instillation of varying doses of nano-sized titanium dioxide (nano-TiO2). Female C57BL/6 mice were exposed to ru-
tile nano-TiO2 via single intratracheal instillations of 18, 54, and 162 μg/mouse.Micewere sampled 1, 3, and 28 days
post-exposure. The deposition of nano-TiO2 in the lungs was assessed using nanoscale hyperspectral microscopy.
Biological responses in the pulmonary system were analyzed using DNA microarrays, pathway-speciﬁc real-time
RT-PCR (qPCR), gene-speciﬁc qPCR arrays, and tissue protein ELISA. Hyperspectral mapping showed dose-
dependent retention of nano-TiO2 in the lungs up to 28 days post-instillation. DNA microarray analysis revealed
approximately 3000 genes that were altered across all treatment groups (±1.3 fold; p b 0.1). Several inﬂammatory
mediators changed in a dose- and time-dependent manner at both themRNA and protein level. Although no inﬂux
of neutrophilswas detected at the lowdose, changes in the expression of several genes and proteins associatedwith
inﬂammationwere observed. Resolving inﬂammation at themedium dose, and lack of neutrophil inﬂux in the lung
ﬂuid at the low dose, were associated with down-regulation of genes involved in ion homeostasis and muscle reg-
ulation. Our gene expression results imply that retention of nano-TiO2 in the absence of inﬂammationover timemay
potentially perturb calcium and ion homeostasis, and affect smooth muscle activities.
Crown Copyright © 2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Titanium dioxide (TiO2) is generally considered to be chemically inert
because it is highly insoluble, thermally stable, and non-ﬂammable. How-
ever, rats exposed to high doses of pigment-grade and ultraﬁne TiO2 dust
by inhalation or instillation develop lung cancer (Heinrich et al., 1995). In
addition, the International Agency for Research on Cancer has classiﬁed
pigment-grade TiO2 (microparticles with size range of 100–200 nm) as
a possible human carcinogen (group 2B) (IARC, 2010; Iavicoli et al.,
2011) based on animal and cell culture data, but there is little evidence
for TiO2-mediated carcinogenic effects in humans. TiO2 is produced pri-
marily as aggregates or agglomerates of nano-sized particles. It accounts
for 70%of the total productionof pigmentsworldwide. TiO2-nanoparticles
(TiO2-NPs) are extensively used in a wide range of products includingce and Research Bureau, ERHSD,
03A), 50 Columbine Driveway,
.
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vier Inc. Open access under CC BY-NC-ND paints, coatings, cosmetics, and sunscreens (Liao et al., 2008; Madl and
Pinkerton, 2009; Park et al., 2009). As a result of the high production
volume and extensive applications of powdered TiO2, reasonable risks
for exposures through inhalation or via other routes are anticipated.
TiO2-NPs exhibit unique physico-chemical properties associated with
their nano-size, which alters their biological behaviors at the cellular, sub-
cellular, and protein levels resulting in adverse health effects (Liu et al.,
2009; Nemmar et al., 2011; Oberdorster et al., 2000; Warheit et al.,
2007). Thus, a detailed characterization of the tissue-level effects and
mechanisms of action of TiO2-NPs is required in order to establish accept-
able exposure limits.
Lung is a primary target organ of NP exposure via inhalation in oc-
cupational settings. Pulmonary responses are largely driven by the
physico-chemical properties of the NPs, and it is well established
that inhalation of TiO2-NPs induces pulmonary responses that primarily
include inﬂammation. Ferin et al. (1992) were the ﬁrst to demonstrate
that pulmonary responses in rats exposed to TiO2-NPs are greatly
inﬂuenced by particle size (Ferin et al., 1992). These authors also showed
that intratracheal instillation or inhalation of TiO2-NPs induces profound
neutrophilic inﬂammation/inﬁltration, translocation of particles to the
deeper regions of lungs, and longer retention of particles compared to
their microparticulate counterpart. Similar particle size-associated effectslicense.
Table 1
Physical and chemical characteristics of nano-TiO2 (modiﬁed from Halappanavar et al.,
2011; Hougaard et al., 2010).
Description Composition
Phase Rutile
Form Powder
Structural formula Ti2O4
Average crystalline size 20.6 ± 0.3 nm
Minimum crystalline size [100]a 14.4–15.5 nm
Maximum crystalline size [001]a 38.4 nm
Speciﬁc surface area 107.7 m2/g
Elements Content [wt%]
Silicon 5.61
Titanium 42.44
Aluminum 2.42
Zirconium 0.86
Sodium 0.45
Oxygenb 35.24
Coating Silicon, aluminum, zirconium and polyalcohol
a Estimate of the average crystalline size along the shortest and longest crystallographic
direction.
b Calculated by difference from 100 wt.%.
251M. Husain et al. / Toxicology and Applied Pharmacology 269 (2013) 250–262on pulmonary inﬂammation in rats were also observed by Renwick et al.
(2004). Additional evidence suggests that the adverse pulmonary effects
associated with TiO2-NPs are further ampliﬁed if the NPs are surface-
coated with alumina or amorphous silica (Warheit et al., 2007). Inﬂam-
matory response to TiO2-NPs varies depending on the crystalline form
(Grassian et al., 2007), with mixed rutile/anatase forms exhibiting in-
creased toxicity over other types of TiO2-NPs driven by the larger sur-
face areas of mixed TiO2-NP types (Warheit et al., 2007). Thus, these
and other studies (reviewed in (Johnston et al., 2009)) ﬁrmly establish
that TiO2-NPs elicit pulmonary toxicity and tissue injury, and that the
toxicity is based on several physical and chemical properties.
Several studies have shown that ultraﬁne particles or NPs effec-
tively evade primary phagocyte-mediated clearance mechanisms in
the lungs and hence migrate to the deeper interstitial regions of the
lungs where they are retained over long periods of time (Ferin et al.,
1992; Katsnelson et al., 2010). Other studies have suggested that exces-
sive pulmonary retention and accumulation of particlesmay lead to lung
injury and/or enhanced risks of developing cancer (Bermudez et al.,
2002, 2004; Heinrich et al., 1995). However, most of these studies used
physiologically irrelevant doses and thus, the biological implication of
low dose exposure to TiO2-NPs, and the underlying molecular mecha-
nisms of the observed pulmonary responses, remain largely unknown.
Additionally, very few studies have examined the effects of retained par-
ticles following low dose exposures on pulmonary systems.
We (Saber et al., 2012) recently compared pulmonary response
in mice following single instillation doses of 18, 54 and 162 μg
of nano-TiO2/mouse, corresponding to 1.5, 5 and 15 working days
at the Danish occupational exposure level for TiO2 (6.0 mg Ti/m3–
9.75 mg TiO2/m3) at three different post-exposure time points, and
showed dose- and time-dependent pulmonary neutrophilic inﬂam-
mation. Interestingly, the lowest dose in this study did not elicit any
pulmonary inﬂammation as measured by inﬂammatory cellular inﬂux
in the bronchoalveolar lavage ﬂuid (BAL). Based on these results a No
Observed Effect Level (NOEL) for nano-TiO2 of 19 cm2 was derived for
mice, corresponding to the lowest tested dose (Saber et al., 2012).
It could be hypothesized that the lack of inﬂammatory cell inﬂux in
the BAL at the low doses observed in the study described above is a re-
sult of ﬁrst-order rates of clearance in the low dose range. In the present
study we rationalized that the lack of observable changes in inﬂamma-
tory cell inﬂux reported by Saber et al. (2012), is actually the result of di-
minished induction of clearance mechanisms at low dose NP exposures,
and that NPswill thus still be present in the lungs even in the absence of
inﬂammation. To test our hypothesis we used nanoscale hyperspectral
microscopy to measure nano-TiO2 retention in the lungs of the same
mice used by Saber et al. (2012), in parallel with pulmonary gene and
protein expression proﬁling, to study dose and time-related responses.
We expected to ﬁnd signiﬁcant retention of particles in lungs at all
doses over extended periods of time resulting in perturbations of normal
biological functions. An additional objective for this study was to gener-
ate testable hypotheses for novel mechanisms involved in pulmonary
effects induced by low doses of nano-TiO2.
Materials and methods
The experimental samples used in this study were generated in an
earlier study; the animals, characterization of particles, exposure, and
exposure monitoring are previously described in Saber et al. (2012)
and are brieﬂy outlined below.
Animals
Five-to-seven week old female C57BL/6 mice were purchased from
Taconic (Ry, Denmark) and were acclimatized for 1–3 weeks prior
to the commencement of the experiment. Mice were maintained in
groups in polypropylene cages with sawdust bedding and enrichment,
at 20–22 °C room temperature and relative humidity of 40–60% witha 12 h light-to-dark cycle. All mice received food and water ad libitum
throughout the experiment. All animal experiments were approved by
the Danish “Animal Experiments Inspectorate” and performed according
to their guidelines for ethical conduct in the care and use of animals in
research.
Particle characterization and preparation of exposure stock
The nanomaterial used in this study was an ultraﬁne powder of
surface coated rutile TiO2 also known as UV-Titan L181 (Kemira, Pori,
Finland) with an average crystallite size of 20.6 nm and surface area of
107.7 m2/g, and is termed ‘nano-TiO2’ throughout this article. Details of
the particle characterization were described previously (Halappanavar
et al., 2011; Hougaard et al., 2010), and are summarized in Table 1.
Naïve C57BL/6 mice were ﬂushed twice with 0.6 ml of 0.9% NaCl to
obtain approximately 1 ml of bronchoalveolar lavage ﬂuid (BAL). BAL
was centrifuged at 400 g for 10 min at 4 °C to remove cells. The super-
natantwas used in the dispersant liquid. A total of 4.05 mgof nano-TiO2
was suspended in 1 ml ofMilliQwater containing 0.9%NaCl and 10% v/v
acellular BAL. Particle suspensions were prepared by sonicating the
samples using an S-450D soniﬁer (Branson Ultrasonics Corp., Danbury,
CT, USA) at 10% amplitude for a total of 16 min on ice with alternating
10 s pulses and pauses. Three different dilutions of nano-TiO2were pre-
pared and used in this experiment: 162 μg, 54 μg (1:3 dilution of the
162 μg), and 18 μg (1:3 dilution of the 54 μg). Control vehicle solutions
were prepared without the nano-TiO2 (MilliQ water containing 90%
of 0.9% NaCl and 10% acellular BAL ﬂuid). The doses 18, 54, and
162 μg/mouse are equivalent to 1.5, 5, and 15working days at the Danish
occupational exposure level for TiO2 (6.0 mg Ti/m3–9.75 mg TiO2/m3),
respectively (Saber et al., 2012).
Exposure of mice and harvesting of tissue
Each treatment group consisted of a minimum of 6 animals. Mice in
the experimental groups received a single intratracheal instillation of 18
(low dose), 54 (medium dose), or 162 μg (high dose) of nano-TiO2 in
a 40 μl suspension as described above, followed by 150 μl air with a
250 μl SGE glass syringe (250F-LT-GT, MicroLab, Aarhus, Denmark).
Intratracheal instillation was performed at 37 °C on heating plates,
under anesthesia using Hypnorm® (fentanyl citrate 0.315 mg/ml
and ﬂuanisone 10 mg/ml from Janssen Pharma) and Dormicum®
(Midazolam 5 mg/ml from Roche). Control mice received 40 μl of disper-
sant vehicle only. Following instillation, mice were under observation
until they recovered from anesthesia. Mice were allowed to recover for
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under anesthesia (Hypnorm/Dormicum). Blood, BAL ﬂuid, and tissues
were collected. Lung tissues from experimental and control mice were
cut into small pieces, stored in cryogenic vials, and snap frozen immedi-
ately in liquid nitrogen. All tissues were stored at−80 °C until analysis.
All analyses including microarray, validation of microarray results, pro-
tein analysis, and microscopic imaging for detection of particles were
conducted on the left lobe of the lung tissue.
Detection of nano-TiO2 in lung tissue
Frozen lung tissue samples (n = 2–3) from low and medium dose
groups sampled on day 1 and day 28 andmatched controlswere embed-
ded in parafﬁn. Parafﬁn-embedded tissues were sliced into 5 μm thick
sections and stained with hematoxylin-eosin (H-E). H-E stained lung
tissue sections (two sections per sample) were sent to CytoViva, Inc.
(Auburn, AL, USA) for hyperspectral imaging and quantitative mapping
of nano-TiO2 particles in the lungs. The proprietary hyperspectral imag-
ing technology uses a nano-scalemicroscope and a darkﬁeld-based opti-
cal illuminator to focus light on samples, yielding images with improved
contrast and signal-to-noise ratio. Such imaging technique takes advan-
tage of the intrinsic light scattering properties of the particle of interest
(e.g., nano-TiO2 particles). The hyperspectral imager consists of a con-
centric imaging visible and near-infrared (VNIR) spectrophotometer
(400–1000 nm)with integrated CCD camera, and is controlled by Envi-
ronment for Visualization (ENVI 4.8) software for hyperspectral image
analysis. The images (100× magniﬁcation) were captured using a Dage
Excel Color Cooled-M camera that is attached to an Olympus BX 43 opti-
cal microscope. In order to aid the identiﬁcation and image analysis
process, a reference spectral library of nano-TiO2 was created prior to
the analysis of the actual sample images using a customized software
analysis program, and coded experimental samples were compared to
those in the reference library. Samples were decoded after the comple-
tion of analysis to examine particle-related retention.
Total RNA extraction and puriﬁcation
The total tissue for RNA extraction varied between 10 and 15 mg from
each animal. In order to ensure unbiased analysis of tissue response, total
RNA was isolated from randomly sectioned (weighing 10–15 mg) left
lung lobe. RNA was isolated from 5 to 6 individual animals from each
of the treatment and control groups using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and puriﬁed using RNeasy Plus Mini kits (Qiagen,
Mississauga, ON, Canada) according to the manufacturer's instruction.
Total RNA concentration was measured using a NanoDrop 2000 spectro-
photometer (Thermo Fisher Scientiﬁc Inc., Wilmington, DE, USA), and
RNA quality and integrity were assessed using an Agilent 2100
Bioanalyzer (Agilent Technologies, Inc., Mississauga, ON, Canada)
according to the manufacturer's instruction. All samples showed RNA
integrity numbers of 7 and above, indicating high quality RNA, and
were used to conduct microarray and qPCR experiments.
Microarray hybridization
Total RNA (250 ng) samples from individual mice (n = 5–6 per
experimental and control group) and from universal reference total
RNA (Agilent Technologies, Inc., Mississauga, ON, Canada) were used to
synthesize double-stranded cDNA and cyanine labeled cRNA using
Quick Amp Labeling Kit (Agilent Technologies Inc., Mississauga, ON, Can-
ada) according to themanufacturer's instructions. Control and nano-TiO2
treated cRNAswere labeledwith cyanine 5-CTP, and reference RNAswere
labeledwith cyanine 3-CTP using a T7 RNA polymerase in vitro transcrip-
tion kit (Agilent Technologies Inc., Mississauga, ON, Canada) and puriﬁed
using RNeasy Mini kits (Qiagen, Mississauga, ON, Canada). Each experi-
mental cRNA sample was mixed with an equimolar amount of reference
cRNA and was hybridized to Agilent mouse 4 × 44 oligonucleotidemicroarrays (Agilent Technologies Inc., Mississauga, ON, Canada) for
17 h in a hybridization chamber at 65 °C with a rotation speed of
10 rpm. Arrays were washed according to manufacturer's protocols
(Agilent Technologies Inc., Mississauga, ON, Canada) and scanned on an
Agilent G2505B scanner. Data from the scanned images were extracted
using Agilent Feature Extraction software version 9.5.3.1. All microarray
data from this study are available at theNational Center for Biotechnology
Information (NCBI) and Gene Expression Omnibus (GEO) databases. GEO
accession number for these ﬁles is GSE41041.
Statistical analysis of microarray data
A reference randomized block design (Kerr, 2003; Kerr and
Churchill, 2007) was used to analyze gene expression microarray data.
Data were normalized using LOcally WEighted Scatterplot Smoothing
(LOWESS) (Cleveland, 1979) regression modeling method and statisti-
cal signiﬁcance of the differentially expressed genes was determined
using MicroArray ANalysis Of VAriance (MAANOVA) (Wu et al., 2003)
in R statistical software (http://www.r-project.org). The Fs statistic
(Cui et al., 2005) was used to test the treatment effects and p-values
were estimated by the permutation method using residual shufﬂing.
The false discovery rate (FDR) multiple testing correction (Benjamini
and Hochberg, 1995) was applied to minimize any false positives. Fold
change calculationswere based on the least-squaremeans. Genes show-
ing expression changes of at least 1.3 fold in either direction compared
to their matched controls and having p-values of less than or equal to
0.1 (p ≤ 0.1) were considered as signiﬁcantly differentially expressed
and were used in the downstream analysis. We applied a liberal ap-
proach since we were looking for effects in the low dose range in the
absence of any observable phenotype.
Functional and pathway analysis of differentially expressed genes
Functional gene ontology (GO) analysis of the differentially ex-
pressed genes was performed using the Database for Annotation, Vi-
sualization and Integrated Discovery (DAVID) v6.7 (Huang da et al.,
2009). Benjamini–Hochberg corrected GO processes with a Fisher's
exact p ≤ 0.05 were considered to be signiﬁcantly enriched (over-
represented). Speciﬁc biological pathways associated with the differ-
entially expressed genes were identiﬁed using Ingenuity Pathway
Analysis (IPA, Ingenuity Systems, Redwood City, CA, USA) andMetaCore
(Thomson Reuters Scientiﬁc Inc., Philadelphia, PA, USA) software. Path-
wayswith a Fisher's exact p-value of≤0.05 (p ≤ 0.05)were considered
for discussion. The pathway analysis methods employed in the present
study enable the extraction of biologicallymeaningful information from
a long list of differentially expressed genes. The quality and annotation
of different pathway analysis packages vary. Therefore, the methods
employed in our study are considered a starting point, and are used to
direct future research. For a detailed review on the limitations of the
present pathway analysis approaches please refer to Khatri et al. (2012).
Real-time PCR (qPCR) validation of microarray data
Mouse inﬂammatory cytokines and receptors (PAMM-011A,
SABiosciences, Frederick, MD, USA) and custom PCR arrays were
used to validate 126 genes in total. Genes for the custom PCR array
(CAPM11274, SABiosciences, Frederick, MD, USA) were selected based
on their established roles in biological processes such as acute phase
response, ion homeostasis, lipid metabolism, and muscle regulation,
and exhibited fold changes of at least ±1.3 (p ≤ 0.1). Approximately
800 ng of the total RNA (n = 3 per group) from each of the experimen-
tal and control groups ofmicewas reverse transcribed using an RT2 ﬁrst
strand cDNA synthesis kit (SABiosciences, Frederick, MD, USA). qPCRs
were conducted using RT2 SYBR Green qPCR Master Mix in a CFX96
Real-Time System (BioRad Laboratories, Mississauga, ON, Canada)
according to the manufacturer's instructions. Threshold cycle (Ct) values
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genes, and relative expression of the differentially expressed genes was
determined using online PCR array data analysis software (SABiosciences,
Frederick, MD, USA). The correlation between the qPCR and microarray
fold changes of the validated genes was determined using Spearman's
rank correlation analysis (Spearman, 1904) in R statistical software. A
Shapiro–Wilk normality test (Shapiro andWilk, 1965) for the fold change
datasets was performed prior to the correlation analysis to identify if the
data were normally distributed.
Expression analysis of inﬂammatory proteins
Total protein from the frozen lung tissues (n = 3) from experimen-
tal and control micewas extracted using Bio-Plex Cell Lysis Kits (BioRad
Laboratories, Mississauga, ON, Canada) and quantiﬁed using Bradford
protein assay kits (Bio-Rad Laboratories, Mississauga, ON, Canada).
Expression of mouse pro-inﬂammatory cytokines was assessed using
ProMouse Cytokine 23-plex and 9-plex assay kits (BioRad Laboratories,
Mississauga, ON, Canada) according to the manufacturer's instructions
in a Bio-Plex 200 system (BioRad Laboratories, Mississauga, ON, Canada).
Brieﬂy, 100 μg of each lysate was diluted with themanufacturer supplied
sample diluents. Anti-cytokine/chemokine antibody-conjugatedmagnet-
ic beads were immobilized in each individual well of the 96 well ﬁlter
plates using a vacuum manifold. Plates were washed twice, and 50 μl
of pre-diluted standards and sample lysateswas added to each of the des-
ignated well. Plates were shaken at room temperature for 30 min at
350 rpm. Following 3 washes, plates were incubated for 30 min with
25 μl of pre-diluted multiplex detection antibody. Plates were washed 3
times and incubated with 50 μl of pre-diluted streptavidin-conjugated
phycoerythrin for 10 min. Following a ﬁnal 3-step wash, plates were in-
cubated with 125 μl of assay buffer in each well and were analyzed
using the Bio-Plex protein assay system. The concentration of each cyto-
kine and chemokine was determined using Bio-Plex Manager Version
6.0 software.
Results
The pulmonary inﬂammatory response was assessed to investigate
the impact of nano-TiO2 deposition inmouse lungs bymeasuring BAL dif-
ferential cell counts and the results were published (Saber et al., 2012).
Since the inﬂammatory phenotype reported in Saber et al. (2012) pro-
vides context to the present study, the results are summarized below.
Brieﬂy, exposure to nano-TiO2 induced a signiﬁcant inﬂammatory re-
sponse in the 54 μg dose group on days 1 and 3, and in the 162 μg dose
group across all the post-exposure time points studied. Inﬂammation
was mainly characterized by an increase in the total cellular count and
inﬂammatory neutrophils in BAL. Inﬂammation was pronounced on
day 1 for both of these dose groups and was partially resolved by
28 days post-exposure time. No signiﬁcant changes were observed in
the BAL cellular proﬁles of the 18 μg dose group compared to the controls.
Detection of nano-TiO2 in lung tissue
In order to understand if lack of inﬂammation in the low dose group
is attributed to the efﬁcient clearance of particles, the lungs of mice
exposed to low (18 μg) or high (162 μg) doses of nano-TiO2 sampled
on days 1 and 28 post-exposure were examined for particle retention
using the CytoViva patented VNIR hyperspectral imaging system and
darkﬁeldmicroscopy. Nanoparticles in general have a signiﬁcantly differ-
ent refractive index from the surrounding tissue, stains, and mounting
medium used to process the tissues, which leads to greater scattering
of light in the sections containing NPs and hence their easy detection.
Two reference spectral libraries were made. The ﬁrst library established
a complete spectral proﬁle of the nano-TiO2 used in this study (Fig. 1a).
The second library cataloged a set of bright non-speciﬁc inclusions that
were ﬂuorescing as strongly as the nano-TiO2, but were also found inthe untreated control samples (Fig. 1b). These non-speciﬁc inclusions
are the result of endogenous cellularmaterials ﬂuorescing in all samples.
Images from the treated samples were overlaid with the reference spec-
tral library for nano-TiO2 for accurate and precise detection of nano-TiO2
particles in the exposed samples.
Fig. 1c shows dark ﬁeld (upper panel), dark ﬁeld hyperspectral
(middle panel), and hyperspectral mapping (bottom panel, overlay
of dark ﬁeld hyperspectral imageswith nano-TiO2 reference spectra) im-
ages. Qualitative analysis of particle-laid lung tissues showed aggregated
and agglomerated nano-TiO2 (white inclusions indicated bywhite arrow
heads) in randomparts of the lung tissue increasing in a dose-dependent
manner. A signiﬁcant amount of nano-TiO2was observed in day 1 aswell
as in day 28 post-exposure samples (Fig. 1c, upper panel). We did not
apply a quantitative approach tomeasure the exact numbers of particles
or aggregates. Quantitative analyses would require highly precise local-
ized sectioning to compare the exact same lung regions across the sam-
ples, which was not possible in this study. Thus, it was not possible to
determine if the amount of particles retained in lungs decreasedwith in-
creasing recovery time. Red dots in the bottom panel (Fig. 1c, indicated
by arrow heads) show areas of inclusions that were matched to the
speciﬁc hyperspectral reference library created for nano-TiO2. Bright
inclusions in the control samples did not match with the spectra of
nano-TiO2 (Figs. 1a and b). These results demonstrate dose-dependent
deposition and sustained retention of nano-TiO2 over 28 days following
the exposure for both the lowest and the highest doses.
Gene expression analysis
In order to understand the biological implications of tissue particle
retention in the absence of inﬂammation, whole lung gene expression
proﬁling was conducted on samples from all the doses and time points.
MAANOVA analysis revealed a total of 3452 probes representing 3070
unique genes signiﬁcantly differentially expressed in response to low,
medium and high doses of nano-TiO2 instillation on post-exposure
days 1, 3 and 28. Changes in gene expression were considered signiﬁ-
cant if they showed p-values of ≤0.10 and a fold change ≥1.3 in either
direction (Supplementary Table 1). Since the present study focused on
ﬁnding the effects following very low dose exposures that did not
show any observable biological response as measured by inﬂammatory
cell counts in BAL ﬂuid, we selected a liberal fold change of ±1.3 and
p-value cut-off of p ≤ 0.1. These thresholds are aligned with the
recommended cut-offs by Shi et al. (2008). These authors suggested the
use of fold change ranking in conjugation with a ﬂexible (non-stringent)
p-value threshold in order to generate reproducible differentially ex-
pressed gene lists (Shi et al., 2008).
A principal component analysis (PCA) on all of the differentially
expressed genes revealed a dose and time effect (Supplementary Fig.
1). A total of 1708 genes were signiﬁcantly differentially expressed on
day 1 in at least one of the dose groups compared to controls. Speciﬁcal-
ly, 462, 691, and 1015 transcripts were affected by nano-TiO2 treatment
in the low,medium, and high dose groups respectively. There were only
60 genes in common across the dose groups (Fig. 2a). Most of the genes
onday1were up-regulated. A total of 1255 transcriptswere differential-
ly expressed relative to controls on day 3 including 693, 652, and 620 in
the low, medium, and high dose groups respectively. There were 209
transcripts that were similarly affected across all the dose groups on
day 3 (Fig. 2b), and the majority of the genes on day 3 were down-
regulated. On day 28, a total of 1198 genes were differentially expressed
with 325, 279, and 805 genes changing in the low, medium, and high
dose respectively (Fig. 2c), andwith a fairly equal number of transcripts
being both up- and down-regulated.
Biological functions of differentially expressed genes
GO functional classiﬁcation was used to identify speciﬁc themes
in the gene expression patterns following exposure to nano-TiO2. The
Fig. 1. Identiﬁcation of nano-TiO2 particles in lung tissues. Lung tissues frommice harvested 1 and 28 days following a single intratracheal instillation of low (18 μg) and high (162 μg)
doses of nano-TiO2 were subjected to visible and near-infrared (VNIR) hyperspectral imaging to identify particle retention in these tissues. (a) Reference spectral library from nano-TiO2
exposed tissue. (b) Reference spectral library from control tissue. (c) Dark ﬁeld images from nano-TiO2 exposed tissues (upper panel). Dark ﬁeld hyperspectral images from nano-TiO2
exposed tissues identifying these nanoparticles, which appeared as aggregates of white inclusions (middle panel). Hyperspectral mapping of nano-TiO2 in these tissues appeared as
red dots or aggregates (bottom panel).
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processes with a Fisher's exact p-value ≤0.05 (Benjamini–Hochberg
corrected) were considered signiﬁcantly enriched. The common and
unique biological processes signiﬁcantly enriched in different dose groups
across the time points are shown in Fig. 3.Biological processes affected on day 1. The top common biological
process altered on day 1 in all three doses consisted of 252 genes
(Supplementary Table 2) implicated in immune/inﬂammatory responses,
and was associated with ﬁve speciﬁc GO terms: immune response
[GO:0006955], response to wounding [GO:0009611], inﬂammatory
response [GO:0006954], response to organic substance [GO:0010033],
and chemotaxis [GO:0006935] (Fig. 3; day 1, common GO processes).
In addition to the immune response, genes in the medium dose group
were implicated in various types of metabolism including: fatty acid
metabolic process [GO:0006631], and lipid [GO:0006638] and glycerol
[GO:0006662]metabolic processes (Fig. 3; day 1, unique GOprocesses).
Genes over-represented in these GO processes were predominantly
down-regulated. Unique biological processes affected in the high dose
group included: lipid biosynthetic process [GO:0008610], and choles-
terol metabolic process [GO:0008203], cell proliferation [GO:0008283],
DNA replication [GO:0006260], and extracellular matrix organization
[GO:0030198] (Fig. 3; day 1, unique GO processes).Biological processes affected on day 3. Genes expressed on day 3
weremainly involved inmuscle development and/ormuscle contraction
processes, as indicated by 5 closely related GO biological pro-
cesses commonly enriched in all 3 dose groups: cytoskeleton
organization [GO:0007010], muscle organ development [GO:0007517],
actin ﬁlament-based process [GO:0030029], muscle contraction
[GO:0006936], and striated muscle tissue development [GO:0014706]
(Fig. 3; day 3, common GO processes). A complete list of 66 genes that
were over-represented on day 3 implicated in muscle development
and function is provided in Supplementary Table 3. Unique processes
altered in the medium dose group included microtubule-based move-
ment [GO:0007017, GO:0007018]. Uniquely altered processes in the
low dose group included homeostatic process [GO:0042592], ion ho-
meostasis [GO:0050801], and regulation of body ﬂuid levels
[GO:0050878] (Fig. 3; day 3, unique GO processes).
Biological processes affected on day 28. Muscle regulation (muscle
contraction [GO:0006936] and striated muscle tissue development
[GO:0060537]) were commonly affected in the low and medium dose
groups (Fig. 3; day 28, common GO processes) and consisted of 27 af-
fected genes in these groups (Supplementary Table 4). Some of these
processes were also altered on day 3. Inﬂammatory response (Fig. 3;
day 28, unique GO processes) was uniquely altered in the high dose
group; calcium ion homeostasis [GO:0055074], homeostatic process
Fig. 2. Venn diagrams showing the overlap of genes that were signiﬁcantly differentially expressed in response to low (18 μg), medium (54 μg), and high (162 μg) doses of
nano-TiO2 exposure on (a) day 1, (b) day 3, and (c) day 28 post-instillation.
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medium dose group.
Biological pathway analysis
Canonical pathway analysis was conducted using IPA tools. A total of
14 pathways were commonly signiﬁcantly enriched across all treat-
ment groups (Table 2). There were 7 uniquely affected pathways on
3 days post-exposure, and 4 uniquely perturbed pathways on day 28.
Consistent with affected GO processes, the immune-inﬂammatory re-
sponse pathway was commonly affected on day 1. Calcium signaling,
actin cytoskeleton, and fatty acidmetabolismpathwayswere perturbed
on day 3. The hepatic ﬁbrosis/hepatic stellate cell activation pathway
was signiﬁcantly affected on day 28. A total of 56 genes were related
to the hepatic ﬁbrosis/hepatic stellate cell activation pathway and
these were affected across all dose groups.
qPCR validation of microarray results
A large subset of genes spanning major biological processes/path-
ways altered by the treatmentwas selected for qPCRvalidation. These fo-
cused primarily on genes that are associated with inﬂammation, acute
phase response, ion transport, calcium ion binding, and muscle contrac-
tion. The qPCR results are presented in Fig. 4 and Supplementary Table 5.
Out of the 84 pro-inﬂammatory genes present on the inﬂammatory
chemokine and cytokine array, 74 genes were differentially expressed
(1.3 fold in either direction; p ≤ 0.1) in at least one dose within at least
one time point. Of the 42 genes analyzed by customarray, 38were signif-
icantly altered in treated relative to control mice. A complete list of the
112 validated genes from qPCR experiments is provided in Supplemen-
tary Table 5. Sixty-two of the 112 genes were common to both microar-
ray and qPCR (Fig. 4). A correlation analysis performed on the fold
changes of 62 validated genes showed high correlation as indicated bythe Spearman's rank correlation rho (r) value of 0.89 (p ≤ 0.0001)
(Supplementary Fig. 2).
Tissue expression of pro-inﬂammatory chemokines and cytokines
Most of the inﬂammatory modulators are synthesized and stored in
an endogenous pool; many of them require activation at the post-
transcriptional and translational level. Upon stimulation, these endoge-
nous pools are mobilized therefore the cells/tissues do not immediately
require fresh synthesis of mRNA. Therefore, in order to be sure that we
did not miss anything in the low dose group by focusing on trans-
criptional changes we assessed protein levels of 31 chemokines, cyto-
kines, and their receptors. Due to the limited availability of biological
material, we used a multiplex ELISA assay and therefore not all selected
chemokines and cytokines for protein analysis are matched with those
that showed changes in expression at the gene level. Nineteen of the
31 proteins examined were more expressed on day 1 (T helper (Th)-1
and Th-2 cytokines; e.g., IL-1b, IL-2, IL-5, IL-9, IL-10, IL-12, IL-13, IL-17,
G-CSF, and GM-CSF) in at least one of the dose groups. Seven proteins
were signiﬁcantly up-regulated on day 3 (CCL3, CCL4, FGF Basic, MCSF,
CXCL9, CXCL2, and VEGF) and 8 on day 28 (IL-12(p40), CCL3, CCL4,
FGF Basic, MCSF, CXCL9, CXCL2, and VEGF) compared to their matched
controls (Fig. 5). None of the up-regulated proteins in the low dose
group from day 1 samples showed corresponding increases at the
mRNA level. Only four proteins (CCL2, CCL3, CCL4, and CXCL1) showed
corresponding increases in mRNA levels in the medium and high dose
groups.
Comparison of nano-TiO2 whole body inhalation and intra-tracheal
instillation studies
In a previous study we analyzed pulmonary gene expression pro-
ﬁles of C57BL/6 mice that were subjected to whole body inhalation of
Fig. 3. Gene ontology (GO) analysis of differentially expressed genes. The upper panel shows the GO biological processes that were enriched and were in common among the low, medium,
and high dose groups. The lower panel indicates GO biological processes that were uniquely enriched in the low, medium, and high dose groups. Columns from left to right present the
enrichment of GO biological processes on days 1, 3, and 28, respectively. Results from low, medium, and high dose groups are shown in blue, green, and red bars respectively.
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et al., 2011; Hougaard et al., 2010). Global gene expression was assessed
5 days following the last exposure. The phenotype was characterized by
neutrophilic inﬂammation as measured by BAL cellular differential
counts. A parallel analysis of pulmonary gene expression proﬁles showed
differential expression of 355 genes with a fold change of at least ±1.3
(p ≤ 0.1). These genes mainly belonged to immune-inﬂammatory re-
sponse, acute phase response, chemotaxis, and complement activation
processes. In the present study, similar neutrophil-dominant inﬂamma-
tionwas observed following intratracheal instillation.Moreover, approx-
imately 57% (201/355, p ≤ 0.1 and fold change ±1.3; Supplementary
Table 6) of those genes were commonly differentially regulated in the
lungs in one or more of the treatment conditions. In addition to taking
part in immune-inﬂammatory responses, these common genes also
play a role in muscle contraction, ion/calcium ion homeostasis, and fatty
acid/lipid metabolic processes. For example, some of these commonly
affected genes include Il1b, Saa3, cxcl5, Ly6f, Slc26a4, Lcn2, Noxo1,
cxcl12, ccl7, ccl9, ccl2, ccl17, ccl12, Atp1a2, Myom2, Tnnt2, Fasn, Aacs,
and Ch25h.
Discussion
In this study lung gene expression proﬁles of mice exposed to 3
different doses of nano-TiO2 were analyzed at three different post-
exposure time points in parallel with the analysis of particle retention
in the lungs.
Enhanced darkﬁeld imaging of lung tissue sections demonstrated
that intratracheal instillation of nano-TiO2 resulted in non-uniform de-
position of particles (seen as white inclusions; Fig. 1c) throughout the
lung regions at all of the examined doses and post-exposure time points.Near-infrared hyperspectral image analysis conﬁrmed that the highly il-
luminated white inclusions observed in treated samples corresponded
speciﬁcally to nano-TiO2 (shown in red; Fig. 1c). Particle retention was
observed more in the high dose group than the low doses. Interestingly,
mice exposed to the low dose did not exhibit any signs of pulmonary
neutrophilic inﬂammation, but noticeable particle retention was ob-
served. Moreover, particles were also observed in the lungs of mice
exposed to the high dose group at 28 days post-exposure when inﬂam-
mation is primarily resolving. These ﬁndings suggest: (1) the low dose
(18 μg) was not sufﬁcient to induce neutrophil inﬂux in BAL, or (2)
acute inﬂammation as measured by increased number of inﬂammatory
cells in BAL induced immediately after a low dose of particles was re-
solved within 24 h.
Relatively few studies have shown the retention of NPs in the lung.
Hougaard et al. (2010) found that 21% of the deposited pulmonary
dose inmice exposed by inhalation to the same nano-TiO2 for 11 consec-
utive days at 42 mg/m3 for 1 h was retained 26 days after terminating
the exposure. Each day of this dosing regimen corresponds to a single
4-hour daily exposure at the current Danish occupational exposure
limit of 9.75 mg/m3 TiO2. It is suggested that phagocytic uptake and/or
phagocyte-mediated translocation are the key clearance mechanisms
for particles deposited in airways and alveoli. However, various studies
have found that nano-scale particles evade these mechanisms and
penetrate interstitial regions of lungs. For example, Geiser et al. (2008)
demonstrated that 20 nm TiO2-NPs are not recognized and cleared by
phagocytes in rat lungswithin theﬁrst 24 h following exposure. Instead,
NPs are engulfed within the ﬁrst 24 h via non-speciﬁc processes occur-
ring during the phagocytosis of the surrounding material (Geiser et al.,
2008). These ﬁndings suggest that most of the TiO2-NPs escape the
immediate and primary clearance mechanisms, and are thus free to
Table 2
Signiﬁcantly enriched biological pathways in the low, medium and high doses of nano-TiO2 exposed mice sampled 1, 3 or 28 days following the single initial exposure.
Pathways Low dose Medium dose High dose
No. of genes Fisher's p-value No. of genes Fisher's p-value No. of genes Fisher's p-value
Day 1
Acute phase response signaling 8 0.040 21 0.000 44 0.000
LXR/RXR activation 7 0.019 21 0.000 40 0.000
Atherosclerosis signaling 8 0.005 10 0.015 27 0.000
LPS/IL-1 mediated inhibition of RXR function 9 0.047 15 0.015 26 0.000
Hepatic ﬁbrosis/hepatic stellate cell activation 9 0.005 16 0.000 24 0.000
Communication between innate and adaptive immune cells 10 0.000 8 0.004 14 0.000
Role of pattern recognition receptors in recognition of bacteria
and viruses
10 0.000 8 0.037 13 0.005
IL-17A signaling in ﬁbroblasts 4 0.009 4 0.049 12 0.000
Crosstalk between dendritic cells and natural killer cells 5 0.029 7 0.028 10 0.013
TNFR2 signaling 5 0.000 4 0.026 7 0.001
MIF regulation of innate immunity 7 0.000 5 0.021 6 0.032
MIF-mediated glucocorticoid regulation 6 0.000 4 0.037 5 0.041
Role of IL-17A in psoriasis 2 0.023 3 0.007 5 0.000
Pathogenesis of multiple sclerosis 2 0.014 2 0.040 4 0.001
Day 3
Calcium signaling 22 0.000 23 0.000 17 0.000
ILK signaling 16 0.000 17 0.000 12 0.026
Actin cytoskeleton signaling 14 0.006 17 0.001 13 0.044
Cellular effects of sildenaﬁl 11 0.002 14 0.000 9 0.044
Fatty acid metabolism 11 0.001 8 0.025 8 0.044
Hepatic ﬁbrosis/hepatic stellate cell activation 9 0.026 12 0.002 13 0.001
Aryl hydrocarbon receptor signaling 9 0.022 12 0.001 12 0.003
Day 28
Hepatic ﬁbrosis/hepatic stellate cell activation 13 0.000 12 0.000 12 0.013
Signaling by Rho family GTPases 9 0.020 7 0.047 17 0.017
Cdc42 signaling 6 0.025 5 0.036 11 0.019
Differential regulation of cytokine production in intestinal epithelial
cells by IL-17A and IL-17F
2 0.050 2 0.035 4 0.010
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and 280 nm iron oxide particles and found that 22 nm particles were
more readily embedded in the lung interstitium (Zhu et al., 2008).
Size-dependent particle uptake bymacrophageswas also demonstrated
in rats using iridium and polystyrene particles (Semmler-Behnke et al.,
2007). Despite the fact that ~50% of inhaled particles were immediately
available for uptake by phagocytes in BAL, this study revealed that less
than 20% of them were associated with phagocytic macrophages.
Hougaard et al. (2010) showed that ~25% of the deposited pulmonary
dose is retained up to 5 days, and 21% up to 26 days post-exposure fol-
lowing nano-TiO2 inhalation in mice. These results collectively suggest
that the observed pulmonary particle retention in our present study in
all dose groups across the different post-exposure time points could
be the combined result of three potential factors: (1) inability to gener-
ate sufﬁcient chemotactic signaling to induce phagocytic inﬁltration;
(2) failed phagocytic recognition; and (3) timely engulfment and rapid
translocation to interstitial lung spaces and inefﬁcient clearance.
Inﬂammation is routinely used as a measure of pulmonary response
to particle exposures. We thus sought to examine whether the lack of
inﬂammation (low dose) or diminished inﬂammation (late time point)
observed in our study is truly reﬂective of a lack of biological or toxico-
logical response in the lungs following nano-TiO2 exposure. To do this,
we quantiﬁed changes in global pulmonary gene expression for all
doses and post-exposure time points in our experiment. As expected,
we observed large changes in the expression of genes associated with in-
ﬂammatory processes, which were both dose- and time-dependent.
GO ontology analysis of differentially expressed genes revealed en-
richment in four main functional groups; inﬂammation and immune
response, lipid metabolism, muscle regulation, and ion homeostasis.
Several genes encoding complements, cytokines, chemokines, and
acute phase responders, including C3, Il1b, Ccl4, Ccl17, Cxcl5, Saa1,
Saa2, Saa3, S100a8, S100A9, and Nfkbiawere signiﬁcantly up-regulatedin this study, indicating the recruitment of leukocytes, predominantly
neutrophils (Saber et al., 2012) and induction of acute phase signaling.
Pathway speciﬁc PCR arrays containing 84 different cytokines and
chemokines were used to conﬁrm the majority of these changes
(Fig. 4 and Supplementary Table 6). Although the low dose group did
not show any evidence of cellular inﬁltration in BAL (Saber et al.,
2012), various genes associated with inﬂammation were perturbed in
these samples, albeit to a lesser extent than the higher doses. This ﬁnd-
ing is consistentwith the hypothesis that inﬂammatory signaling occurs
even at low doses, but is insufﬁcient to cause measurable inﬂux of
inﬂammatory cells in lung lavages.
Despite the lack of neutrophilic inﬁltration in BAL and the somewhat
subtle changes in the expression of inﬂammatory genes in lung tissues
of mice in the low dose group, we observed signiﬁcant increases in pro-
tein synthesis of 17 inﬂammatorymediators in these samples including
IL-2, IL-5, IL-9, IL-10, IL-12, IL-13, IL-17, CCL11, GM-CSF, IFN-g, CXCL1,
CCL2, CCL3, CCL4, FGF-basic, MCSF, and VEGF. These results again sug-
gest that exposure to the low dose led to the initiation of transient
chemotactic signaling, but that this signaling may have been below
the threshold level required to initiate a respiratory burst leading to
neutrophil inﬂux in BAL. Alternately, the rapid interstitialization of
particles may have resulted in activation of interstitial macrophages,
creating a chemotactic gradient in lungs that shifts the inﬂammatory
inﬂux to the interstitium leading to decreased cellular inﬂux in the alve-
olar space (Ferin et al., 1992; Oberdorster et al., 1992).
Differential cellular count of inﬂammatory cells in BAL ﬂuid is an ac-
ceptedmarker of lung response following exposure to particles (Warheit
et al., 1991). Based on lack of inﬂammatory cell inﬂux in BAL ﬂuid, many
studies have claimed that TiO2 particles are not toxic. Our results show
no increases in inﬂammatory cell inﬂux in BAL ﬂuid following exposure
to low doses of TiO2. However, our microarray results revealed signiﬁ-
cant alteration in the expression of a few inﬂammatory genes. ELISA
Fig. 4. Validation of genes identiﬁed as signiﬁcantly differentially expressed in microarray experiment by qPCR. A total of 62 genes from the microarray experiment were also
examined in the qPCR experiment in either of the low, mediumor high dose groups in samples from: (a) day 1, (b) day 3, and (c) day 28 post-instillation periods. All genes frommicroarray
and qPCR experiments had the same directional fold changes of at least±1.3with a p-value of≤0.1. Please note that no genes from the low dose group on day 1met this threshold. The bars
in yellow represent transcripts measured in microarray experiments and the bars in brown represent transcripts measured with qPCR.
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modulators including CXCL1 and CXCL2. These results suggest that dif-
ferential BAL counts are not sensitive enough to pick up effects following
low dose exposures, and that assessment of genes and proteins associat-
ed with inﬂammation may provide a more sensitive measure of the pul-
monary response.
Importantly, many of the genes in the perturbed pathways noted in
this studywere also up-regulated inmouse lungs followingwhole-body
inhalation (1 h/day for 11 consecutive days) of 40 mg UV-Titan/m3 of
the same nano-TiO2 particles tested by Halappanavar et al. (2011).
The 40 mg TiO2/m3/h exposure corresponds to the 8-hr time weighted
average (TWA) Danish occupational exposure limit (At-vejledning,
2007). If it is assumed that 9% of the inhaled particle mass ends up in
the respiratory system, then the total volume of inhaled air per hour
would be 1.8 l/h (Hougaard et al., 2010) in an 8 hworking day. In com-
parison, the doses 18, 54 and 162 μg/mouse used in the present study
are the equivalent of 1.5, 5 and 15 working days at the Danish occupa-
tional exposure level for TiO2 (6.0 mg Ti/m3–9.75 mg TiO2/m3), respec-
tively. Thus, the inhalation dose is similar to the 54 μg dose used in the
present study and indicates that the responses observed are similar to
those observed following exposure to the 54 μg dose on day 1. These re-
sults demonstrate that the inﬂammatory responses following bolus
administration of nano-TiO2 are comparable to those observed follow-
ing inhalation, a physiological route of exposure to particles in the envi-
ronment. Thus, it is reasonable to argue that the low-dose instillationresults observed in this study are relevant to those from inhalation
study by Halappanavar et al. (2011).
Chronic persistent inﬂammation, pulmonary ﬁbrosis, and lung tu-
mors have been documented in rats following chronic and subchronic
inhalation of low toxicity ultraﬁne titanium dioxide particles (reviewed
in (Johnston et al., 2009)). However, it has been argued that these studies
use very high doses that lead to excessive accumulation of particles and
saturation of phagocyte-mediated clearance mechanisms in lungs, and
are thus less physiologically relevant. Although very little is known
about the effects of prolonged retention of low levels of particles in the
lungs, retention and accumulation of particles over extended periods of
time are postulated to lead to increased lung particle burden and en-
hanced risk of developing small airway cancer. In the present study we
extend our dose down tomuch lower thanwhat has been used in earlier
studies (Ferin et al., 1992; Grassian et al., 2007; Renwick et al., 2004;
Warheit et al., 2007) and reviewed in Johnston et al. (2009) and demon-
strate signiﬁcant retention of particles in the lungs even at this low dose.
We hypothesize that low levels of particle retention and accumulation
over time (leading to persistent particle presence in alveolar or inter-
stitial spaces) might hinder air movement, alter lung smooth muscle
contraction activities, and induce tissue foreign body reaction leading
to tissue scaring and tissue ﬁbrosis. In support of this hypothesis gene
expression and pathway analysis revealed muscle regulation and ion
homeostasis to be signiﬁcantly altered in the nano-TiO2 exposed mouse
lungs. Speciﬁcally, we observed down-regulation of several genes
Fig. 5. Analysis of proteins involved in pro-inﬂammatory response in the lungs of experimental mice exposed to nano-TiO2 compared to controls on (a) and (b) day 1, (c) day 3, and
(d) day 28 post-instillation periods. The bars in blue, green, and red represent proteins expressed in response to low (18 μg), medium (54 μg), and high (162 μg) doses of nano-TiO2
exposure respectively. The y-axis shows the fold change ± SE of exposed relative to control mice. Statistical signiﬁcance was calculated using Student's t-test. *p ≤ 0.1; **p ≤ 0.05;
***p ≤ 0.01; and ****p ≤ 0.001.
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Fig. 6. Theassociations andpathways that are perturbed following low-dose exposure to nano-TiO2 that linkparticle retention and response to potential longer-termhealth outcomes. Genes
that are shownwith a red or green circle were up- or down-regulated, respectively. Genes with circles that are colored both red and green circles hadmixed expression (up-regulated at one
time point and down-regulated in another time point). NF-KB, c-Fos and cyclic AMP dependent PKA are indirectly connected to the genes shown; however, are not speciﬁcally altered in our
data set. The green arrows connecting genes/proteins represent positive regulation/activation; the brown arrows connecting genes/proteins represent negative regulation/inhibition; the
grey arrows connecting genes/proteins represent unspeciﬁed regulation.
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late muscle contraction and calcium homeostasis 3 and 28 days post-
instillation. The response was much more pronounced on day 28, with
dramatic down-regulation of several genes implicated in ion homeosta-
sis, calcium binding, muscle contraction and development, and cytoskel-
eton organization (Fig. 4). Of note, the perturbations in the expression of
genes associated with ion homeostasis and muscle functions were inde-
pendent of the inﬂammatory status. The effects on ion homeostasis were
prominent only on days 3 and 28 following low andmedium dose expo-
sures; in contrast, these time points and doses showed little or no inﬂam-
mation. Similar resolution of inﬂammation in the presence of substantial
particle burden was also reported in a study conducted by Ferin et al.
(1992). These authors suggested that inﬂammatory reaction could be
an indication of lung responses occurring during the exposure processand does not necessarily reﬂect the lung burden of particles. Our results
together with those of Ferin et al. (1992) suggest that inﬂammationmay
not be the underlying factor inﬂuencing the gene expression changes as-
sociated with ion homeostasis; rather, these effects are potentially the
results of persistent and prolonged retention of particles in the lungs.
Thus, we speculate that the absence of inﬂammation resulting in the
prolonged conﬁnement of particles to one place is a prerequisite to se-
questration of ions around the particle deposition sites, leading to imbal-
ances in ion homeostasis and deregulation ofmuscle functions. Although
a clear evidence in support of this hypothesis could not be provided in
the present study, our results are indicative of particle-speciﬁc effects.
Calcium inﬂux and signaling regulate neutrophil activation and neu-
trophil mediated inﬂammatory processes in the lungs (Burgos et al.,
2011; Tintinger et al., 2005). Imbalance in calciumhomeostasis following
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muscle in the lungs (Perez-Zoghbi et al., 2009). Gatti et al. (2008) used
a rodent implantation model to evaluate the effects of different
nanomaterials and corresponding bulk materials implanted for 6–
12 months on subcutaneous ormuscular tissues and found that sites im-
planted with TiO2-NPs developed intramuscular foreign body granulo-
mas and moderate ﬁbrosis surrounded by macrophages and giant cells
(Gatti et al., 2008). Moreover, nano-TiO2 exposure caused an increase
in the generation of Fe, Na, S, and P ions close to the particle deposition
site and spherical Ca–P precipitates containing Fe and Zn, speciﬁcally ob-
served at 12 months post-implantation period. Sequestration of ions,
such as Ca and P, renders them biologically unavailable (Gatti et al.,
2008). Since these ions play an important role in many signal transduc-
tion pathways, their precipitation will lead to altered homeostasis and
imbalance in cellular functioning. Althoughwe could not conﬁrm the for-
mation of granulomas or analyze ion sequestration at the site of particle
deposition, substantive alterations in the expression of several genes in-
volved in ion homeostasis andmuscle contraction suggest that prolonged
accumulation of particles could trigger airway smooth muscle pathology,
and increase the risk of developing lung conditions such as asthma, chron-
ic obstructive pulmonary disease, and pulmonary ﬁbrosis (Byrne and
Baugh, 2008).
In conclusion (Fig. 6), our combined data indicate that a signiﬁcant
amount of nano-TiO2 particles is deposited in the lungs even following
exposure to very low doses, and that particles are retained in the lungs
for at least 28 days. Although further experiments are needed to conﬁrm
the ideas presented in the present study, our results imply that particle
accumulation over an extended timeframe together with alterations in
the expression of several genes associatedwith ionhomeostasis andmus-
cle functionmay potentially interferewith calcium, ion, and lipid homeo-
stasis, and affect pulmonary smooth muscle contraction. Prolonged
disturbances in ion homeostasis and airway smooth muscle functioning
can potentially contribute to the development of lung diseases such as
pulmonaryﬁbrosis, asthma, and even lung cancers.Moreover, statistically
signiﬁcant changes in the expression of several genes and proteins in-
volved in vital lung functions in the absence of any observable inﬂamma-
tion call for a careful re-evaluation of particle induced lung toxicity.
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